ホーム>>Signaling Pathways>> PROTAC>> PROTAC Linker>>Azido-PEG8-NHS ester

Azido-PEG8-NHS ester

カタログ番号GC61857

アジド-PEG8-NHS エステルは、抗体薬物複合体 (ADC) の合成に使用される切断可能な 8 ユニット PEG ADC リンカーです。 Azido-PEG8-NHSエステルは、PROTACの合成に使用できるPEGおよびアルキル/エーテルベースのPROTACリンカーでもあります。

Products are for research use only. Not for human use. We do not sell to patients.

Azido-PEG8-NHS ester 化学構造

Cas No.: 1204834-00-3

サイズ 価格 在庫数 個数
100 mg
$180.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Azido-PEG8-NHS ester is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. Azido-PEG8-NHS ester is also a PEG- and Alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs[2].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

References:
[1]. Mahendra Persaud Deonarain, et al. Biological materials and uses thereof. WO2016046574A1.
[2]. Rong Yuan, et al. Viruslike Element-Tagged Nanoparticle Inductively Coupled Plasma Mass Spectrometry Signal Multiplier: Membrane Biomarker Mediated Cell Counting. Analytical Chemistry (Washington, DC, United States) (2019), 91(8), 4948-4952.

レビュー

Review for Azido-PEG8-NHS ester

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Azido-PEG8-NHS ester

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.